Latest Close
₹2,339.00
+3.24%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹2,360.03
200 DMA
₹2,205.35
1 year gain / loss
+₹456.20(+24.23%)
₹1,882.80 → ₹2,339.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Market Cap
₹65,137.45 Cr
P/E
36.23×
Sector -38.72× · above
P/B
6.20×
Sector 4.11× · above
EV / EBITDA
19.17×
Sector 22.21× · below
ROE
28.08%
Sector 0.31%
ROCE
32.70%
Sector 6.48%
ROA
9.03%
Sector -17.12%
Cash Flow / Profit
2.53×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 4,084.24 +3.1% | 643.39 | 482.83 +60.2% |
| Mar 2026 | 3,959.67 +0.4% | 387.77 | 301.32 -25.3% |
| Dec 2025 | 3,945.09 -36.9% | 534 | 403.23 -33.9% |
| Sep 2025 | 6,247.5 | 967.4 | 610.43 |
Dividend
31 Aug 2026 · ₹2.5